Frontier Medicines Stock
HealthTechLooking to sell Frontier Medicines stock or options?
Frontier Medicines has developed a chemoproteomics platform aimed at speeding up the creation of new drugs. This platform combines computational techniques with machine learning to identify and target novel binding sites on proteins, making these sites accessible for small-molecule drug discovery and development. This innovation allows healthcare professionals to offer medications that can alter the trajectory of debilitating diseases, ultimately benefiting patients.
Driehaus Capital Management, ArrowMark Partners, Deep Track Capital, Sphera Funds Management, RA Capital Management, Galapagos (Biotechnology), Woodline Partners, Droia Ventures, Deerfield Management, Berkeley Catalyst Fund, Johnson & Johnson Innovation - JLABS, DCVC Bio, MPM BioImpact.
Our available services for this company
Management Team
Board Members
Frontier Medicines’s stock FAQs
Frontier Medicines is currently a private company. This means that the company is not listed on any public exchange and so there is no public market for its stock. However, there may still be ways to monetize Frontier Medicines stock. Depending on Frontier Medicines’s policies, you may be able to: (1) find a private buyer in the secondary market to purchase your stock, (2) borrow against your stock, or (3) exchange Frontier Medicines stock into the Collective Exchange Fund for a limited partnership interest and then borrow non-recourse against your interest to generate immediate cash. This last alternative can be much quicker and net you more after-tax cash than your other options. An exchange into our fund also reduces your risk by diversifying your holdings out of an over-concentrated position.
Collective Liquidity can provide liquidity to shareholders of Frontier Medicines stock in two ways. First, Frontier Medicines employees can exchange shares into the Collective Exchange Fund and then borrow non-recourse to generate immediate cash. This can net you more after-tax cash than a stock sale. It also reduces your risk by diversifying your holdings out of an over-concentrated position. In some cases, Collective may also be able to purchase your Frontier Medicines stock. Note that all transactions in Frontier Medicines shares are subject to the company’s policies regarding secondary transactions. Schedule a call with a Collective Liquidity representative to learn more about your private market liquidity alternatives.
Frontier Medicines stock is not listed on any public exchange and so there is no public market for its shares. Therefore, there is no single, centralized price for Frontier Medicines stock. Typically, shares of private companies like Frontier Medicines are set with buyers in one off negotiations. Collective Liquidity, however, uses a proprietary algorithm to determine its bids so we almost always have an immediately actionable price for you.
On Jun 2024, Frontier Medicines is reported to have closed an equity financing in which the investors valued the company at $438M. This valuation is typically calculated by multiplying the per share price of the preferred stock sold in the financing by the number of Frontier Medicines shares outstanding assuming the conversion of all stock options, warrants, etc.
Tickers are used to identify company’s shares on public markets like the NYSE or Nasdaq. Because Frontier Medicines is not currently publicly traded, it does not have a ticker symbol.
Frontier Medicines has not yet conducted an initial public offering (“IPO”) and so remains a private company. Though Frontier Medicines is a well-known, successful company, there can be no assurance that it will ever go public or be sold. Because of the risk this imposes on Frontier Medicines shareholders, many investors elect to gain liquidity for at least some of their shares before the IPO. Schedule a call with a Collective Liquidity representative to discuss your private market liquidity alternatives.
